Latest News

Reata Pharmaceuticals sold for $7.3B


Biogen Inc. (BIIB) and Reata Pharmaceuticals (RETA) announced the companies have entered into a definitive agreement under which Biogen has agreed to acquire Reata for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3B.

Inflation Adjusted House Prices 4.4% Below Peak; Price-to-rent index is 7.9% below recent peak

Previous article

Hotels: Occupancy Rate Up 0.5% Year-over-year

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News